Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Diseases of the Thyroid

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 22 articles:
HTML format

Single Articles

    November 2023
  1. KOWKABANY G, Jimenez PB, Sharan S, Bansal S, et al
    Inequities in Time to Treat Thyroid Cancer.
    Anticancer Res. 2023;43:5025-5030.
    PubMed     Abstract available

    October 2023
  2. ZHOU J, Liu J, Zhang KE, Lv J, et al
    High-throughput Sequencing Analysis of Differentially Expressed microRNAs Associated With SREBP1 in Differentiated Thyroid Carcinoma.
    Anticancer Res. 2023;43:4435-4446.
    PubMed     Abstract available

    April 2023
  3. LANDSTROM F, Sandberg J, Reizenstein J
    Life-threatening Airway Complication After Radioactive Iodine Treatment: A Case Report and Review of the Literature.
    Anticancer Res. 2023;43:1853-1855.
    PubMed     Abstract available

    March 2023
  4. NAKAYAMA H, Saito N, Kasajima R, Suganuma N, et al
    Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
    Anticancer Res. 2023;43:1073-1077.
    PubMed     Abstract available

    January 2023
  5. IJAZ K, Yin F
    Papillary Thyroid Carcinoma With Squamous Dedifferentiation: A Potential Diagnostic Pitfall.
    Anticancer Res. 2023;43:255-258.
    PubMed     Abstract available

  6. MATSUO M, Baba S, Hashimoto K, Isoda T, et al
    Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer.
    Anticancer Res. 2023;43:183-190.
    PubMed     Abstract available

    November 2022
  7. CHO JS, Kim HK
    Thyroglobulin Levels as a Predictor of Papillary Cancer Recurrence After Thyroid Lobectomy.
    Anticancer Res. 2022;42:5619-5627.
    PubMed     Abstract available

    September 2022
  8. MILAS ZL, Neelands B, Trufan SJ, Benbow J, et al
    Survivorship Care Plans Improve the Identification of Post-radiation Hypothyroidism After Head and Neck Cancer Treatment.
    Anticancer Res. 2022;42:4429-4437.
    PubMed     Abstract available

    May 2022
  9. KUNTE S, Sharett J, Wei W, Nasr C, et al
    Poorly Differentiated Thyroid Carcinoma: Single Institution Series of Outcomes.
    Anticancer Res. 2022;42:2531-2539.
    PubMed     Abstract available

  10. ACHILLA C, Papavramidis T, Angelis L, Chatzikyriakidou A, et al
    The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer.
    Anticancer Res. 2022;42:2261-2276.
    PubMed     Abstract available

  11. KLIMAITE R, Kazokaite M, Kondrotiene A, Dauksiene D, et al
    Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer.
    Anticancer Res. 2022;42:2289-2299.
    PubMed     Abstract available

  12. HUANG TS, Lee JJ, Huang SY, Cheng SP, et al
    Regulation of Expression of Sterol Regulatory Element-binding Protein 1 in Thyroid Cancer Cells.
    Anticancer Res. 2022;42:2487-2493.
    PubMed     Abstract available

    March 2022
  13. LIU A, Borges PM, Tay YS, Thompson LDR, et al
    Thyroid Follicular Cell-derived Carcinomas in a Background of Multiple Adenomatous Nodules Leading to a Diagnosis of PTEN Hamartoma Tumor Syndrome in an Adult Patient With a Novel RECQL4 Mutation.
    Anticancer Res. 2022;42:1481-1485.
    PubMed     Abstract available

  14. JIN MC, Qian ZJ, Megwalu UC
    Risk of Second Primary Malignancies After External Beam Radiotherapy for Thyroid Cancer.
    Anticancer Res. 2022;42:1359-1365.
    PubMed     Abstract available

    January 2022
  15. MEIROVITZ A, Nisman B, Allweis TM, Carmon E, et al
    Thyroid Hormones and Morphological Features of Primary Breast Cancer.
    Anticancer Res. 2022;42:253-261.
    PubMed     Abstract available

    November 2021
  16. NA YM, Cho JS, Park MH
    Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
    Anticancer Res. 2021;41:5713-5721.
    PubMed     Abstract available

    July 2021
  17. CAO C, Poti SM, Ledgerwood LG, Lai J, et al
    Mixed HPV-related Neuroendocrine Carcinoma and HPV-related Squamous Cell Carcinoma of the Base of Tongue in a Patient With Incidental Identification of Synchronous Metastatic Papillary Thyroid Carcinoma.
    Anticancer Res. 2021;41:3639-3642.
    PubMed     Abstract available

    March 2021
  18. FUKUDA N, Toda K, Ohmoto A, Wang X, et al
    Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Anticancer Res. 2021;41:1683-1691.
    PubMed     Abstract available

  19. MARCHAND-CRETY C, Pascard M, Debreuve-Theresette A, Ettalhaoui L, et al
    Prognostic Factors and Survival Score for Patients With Anaplastic Thyroid Carcinoma: A Retrospective Study from a Regional Registry.
    Anticancer Res. 2021;41:1555-1561.
    PubMed     Abstract available

    December 2020
  20. LORNTZSEN B, Jacobsen AB, GrOholt KK, Sigstad E, et al
    Survival and Surgical Complications in Anaplastic Thyroid Cancer Patients After Completed Multimodal Treatment.
    Anticancer Res. 2020;40:6979-6985.
    PubMed     Abstract available

    November 2020
  21. KIM SH, Cho YK, Huh JH, Kang JG, et al
    Heat Shock Protein 90 Inhibitors AUY922, BIIB021 and SNX5422 Induce Bim-mediated Death of Thyroid Carcinoma Cells.
    Anticancer Res. 2020;40:6137-6150.
    PubMed     Abstract available

  22. NISMAN B, Allweis TM, Carmon E, Kadouri L, et al
    Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer.
    Anticancer Res. 2020;40:6417-6428.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Diseases of the Thyroid is free of charge.